192 related articles for article (PubMed ID: 2473795)
1. Fludarabine: a new agent with major activity against chronic lymphocytic leukemia.
Keating MJ; Kantarjian H; Talpaz M; Redman J; Koller C; Barlogie B; Velasquez W; Plunkett W; Freireich EJ; McCredie KB
Blood; 1989 Jul; 74(1):19-25. PubMed ID: 2473795
[TBL] [Abstract][Full Text] [Related]
2. Fludarabine therapy in chronic lymphocytic leukemia (CLL).
Keating MJ; Kantarjian H; Talpaz M; Redman J; McCredie KB
Nouv Rev Fr Hematol (1978); 1988; 30(5-6):461-6. PubMed ID: 2464794
[TBL] [Abstract][Full Text] [Related]
3. Fludarabine monophosphate: a potentially useful agent in chronic lymphocytic leukemia.
Grever MR; Kopecky KJ; Coltman CA; Files JC; Greenberg BR; Hutton JJ; Talley R; Von Hoff DD; Balcerzak SP
Nouv Rev Fr Hematol (1978); 1988; 30(5-6):457-9. PubMed ID: 2464793
[TBL] [Abstract][Full Text] [Related]
4. Fludarabine: a new agent with marked cytoreductive activity in untreated chronic lymphocytic leukemia.
Keating MJ; Kantarjian H; O'Brien S; Koller C; Talpaz M; Schachner J; Childs CC; Freireich EJ; McCredie KB
J Clin Oncol; 1991 Jan; 9(1):44-9. PubMed ID: 1702145
[TBL] [Abstract][Full Text] [Related]
5. Fludarabine shows promise for some leukemia patients.
Oncology (Williston Park); 1989 Mar; 3(3):14. PubMed ID: 2484283
[No Abstract] [Full Text] [Related]
6. A loading dose/continuous infusion schedule of fludarabine phosphate in chronic lymphocytic leukemia.
Puccio CA; Mittelman A; Lichtman SM; Silver RT; Budman DR; Ahmed T; Feldman EJ; Coleman M; Arnold PM; Arlin ZA
J Clin Oncol; 1991 Sep; 9(9):1562-9. PubMed ID: 1714949
[TBL] [Abstract][Full Text] [Related]
7. Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients.
Leporrier M; Chevret S; Cazin B; Boudjerra N; Feugier P; Desablens B; Rapp MJ; Jaubert J; Autrand C; Divine M; Dreyfus B; Maloum K; Travade P; Dighiero G; Binet JL; Chastang C;
Blood; 2001 Oct; 98(8):2319-25. PubMed ID: 11588025
[TBL] [Abstract][Full Text] [Related]
8. Fludarabine phosphate in the treatment of chronic lymphocytic leukemia.
Keating MJ
Semin Oncol; 1990 Oct; 17(5 Suppl 8):49-62. PubMed ID: 1699283
[TBL] [Abstract][Full Text] [Related]
9. Fludarabine monophosphate in refractory B-chronic lymphocytic leukemia: maintenance may be significant to sustain response.
Angelopoulou MA; Poziopoulos C; Boussiotis VA; Kontopidou F; Pangalis GA
Leuk Lymphoma; 1996 Apr; 21(3-4):321-4. PubMed ID: 8726414
[TBL] [Abstract][Full Text] [Related]
10. Treatment of advanced chronic lymphocytic leukemia by fludarabine. Results of a clinical phase-II study.
Hiddemann W; Rottmann R; Wörmann B; Thiel A; Essink M; Ottensmeier C; Freund M; Büchner T; van de Loo J
Ann Hematol; 1991 Jul; 63(1):1-4. PubMed ID: 1715191
[TBL] [Abstract][Full Text] [Related]
11. Treatment of refractory chronic lymphocytic leukemia with fludarabine phosphate via the group C protocol mechanism of the National Cancer Institute: five-year follow-up report.
Sorensen JM; Vena DA; Fallavollita A; Chun HG; Cheson BD
J Clin Oncol; 1997 Feb; 15(2):458-65. PubMed ID: 9053466
[TBL] [Abstract][Full Text] [Related]
12. Fludarabine monophosphate as salvage for refractory chronic lymphocytic leukaemia.
Pillay GS; Wood L; Jacobs P
S Afr Med J; 1996 Aug; 86(8):949-51. PubMed ID: 8823419
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of oral fludarabine phosphate in previously untreated patients with chronic lymphocytic leukemia.
Rossi JF; van Hoof A; de Boeck K; Johnson SA; Bron D; Foussard C; Lister TA; Berthou C; Kramer MH; Littlewood TJ; Marcus RE; Deconinck E; Montillo M; Guibon O; Tollerfield SM
J Clin Oncol; 2004 Apr; 22(7):1260-7. PubMed ID: 15051774
[TBL] [Abstract][Full Text] [Related]
14. Results of fludarabine and prednisone therapy in 264 patients with chronic lymphocytic leukemia with multivariate analysis-derived prognostic model for response to treatment.
O'Brien S; Kantarjian H; Beran M; Smith T; Koller C; Estey E; Robertson LE; Lerner S; Keating M
Blood; 1993 Sep; 82(6):1695-700. PubMed ID: 8400226
[TBL] [Abstract][Full Text] [Related]
15. [Phase I clinical study of SH L573 (fludarabine phosphate) in patients with chronic lymphocytic leukemia and adult T-cell leukemia/lymphoma].
Arima N; Mizoguchi H; Shirakawa S; Tomonaga M; Takatsuki K; Ohno R
Gan To Kagaku Ryoho; 1999 Apr; 26(5):619-29. PubMed ID: 10234292
[TBL] [Abstract][Full Text] [Related]
16. Phase II study of fludarabine phosphate in multiple myeloma. A Southwest Oncology Group study.
Kraut EH; Crowley JJ; Grever MR; Keppen MD; Bonnet JD; Hynes HE; Salmon SE
Invest New Drugs; 1990 May; 8(2):199-200. PubMed ID: 1696569
[TBL] [Abstract][Full Text] [Related]
17. Fludarabine phosphate. Phase II evaluation in advanced soft-tissue sarcomas.
Pazdur R; Samson MK; Baker LH
Am J Clin Oncol; 1987 Aug; 10(4):341-3. PubMed ID: 2441592
[TBL] [Abstract][Full Text] [Related]
18. Phase I study of fludarabine (2-fluoro-ara-AMP).
Kavanagh JJ; Krakoff IH; Bodey GP
Eur J Cancer Clin Oncol; 1985 Sep; 21(9):1009-11. PubMed ID: 2415365
[TBL] [Abstract][Full Text] [Related]
19. Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy.
Keating MJ; O'Brien S; Lerner S; Koller C; Beran M; Robertson LE; Freireich EJ; Estey E; Kantarjian H
Blood; 1998 Aug; 92(4):1165-71. PubMed ID: 9694704
[TBL] [Abstract][Full Text] [Related]
20. Phase 2 study of a combined immunochemotherapy using rituximab and fludarabine in patients with chronic lymphocytic leukemia.
Schulz H; Klein SK; Rehwald U; Reiser M; Hinke A; Knauf WU; Aulitzky WE; Hensel M; Herold M; Huhn D; Hallek M; Diehl V; Engert A;
Blood; 2002 Nov; 100(9):3115-20. PubMed ID: 12384407
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
